New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease

被引:94
作者
Barter P.J. [1 ]
Puranik R. [1 ]
Rye K.-A. [1 ]
机构
[1] The Heart Research Institute, Sydney, NSW 2050
关键词
High Density Lipoprotein; Adhesion Molecule Expression; High Density Lipoprotein Cholesterol; High Density Lipoprotein Level; Plasma High Density Lipoprotein;
D O I
10.1007/BF02938394
中图分类号
学科分类号
摘要
Several known functions of high-density lipoproteins (HDLs) may contribute to their ability to protect against atherosclerosis. The best known of these functions is the ability to promote cholesterol efflux from cells in a process that may minimize the accumulation of foam cells in the artery wall. However, HDLs have additional properties, including antioxidant, anti-inflammatory, and antithrombotic effects, that may also be anti-atherogenic. Recent in vivo studies in several animal models have demonstrated that HDLs can inhibit acute and chronic vascular inflammation. The fact that these effects can be achieved with very low doses of reconstituted discoidal HDL or even lipid-free apolipoprotein A-I suggests that they may reflect activity of a minor, highly active HDL subpopulation. These results have potentially important clinical implications in regard to managing the acute vascular inflammation states that accompany acute coronary syndrome and acute ischemic stroke. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:493 / 498
页数:5
相关论文
共 46 条
[1]  
Gordon T., Castelli W.P., Hjortland M.C., Et al., High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study, Am J Med, 62, pp. 707-714, (1977)
[2]  
Miller M., Seidler A., Kwiterovich P.O., Pearson T.A., Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol, Circulation, 86, pp. 1165-1170, (1992)
[3]  
Badimon J.J., Badimon L., Fuster V., Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit, J Clin Invest, 85, pp. 1234-1241, (1990)
[4]  
Paszty C., Maeda N., Verstuyft J., Rubin E.M., Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice, J Clin Invest, 94, pp. 899-903, (1994)
[5]  
Plump A.S., Scott C.J., Breslow J.L., Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse, Proc Natl Acad Sci USA, 91, pp. 9607-9611, (1994)
[6]  
Rubin E.M., Krauss R.M., Spangler E.A., Et al., Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature, 353, pp. 265-267, (1991)
[7]  
Duffy D., Rader D.J., Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport, Circulation, 113, pp. 1140-1150, (2006)
[8]  
Durrington P.N., Mackness B., Mackness M.I., Paraoxonase and atherosclerosis, Arterioscler Thromb Vasc Biol, 21, pp. 473-480, (2001)
[9]  
Spieker L.E., Sudano I., Hurlimann D., Et al., High-density lipoprotein restores endothelial function in hypercholesterolemic men, Circulation, 105, pp. 1399-1402, (2002)
[10]  
Bisoendial R.J., Hovingh G.K., Levels J.H., Et al., Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein, Circulation, 107, pp. 2944-2948, (2003)